# A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer

> **NCT06921837** · PHASE1,PHASE2 · RECRUITING · sponsor: **Bolt Biotherapeutics, Inc.** · enrollment: 122 (estimated)

## Conditions studied

- Gastric Cancer Adenocarcinoma Metastatic
- Gastroesophageal Adenocarcinoma

## Interventions

- **DRUG:** BDC-4182

## Key facts

- **NCT ID:** NCT06921837
- **Lead sponsor:** Bolt Biotherapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-26
- **Primary completion:** 2027-05
- **Final completion:** 2029-05
- **Target enrollment:** 122 (ESTIMATED)
- **Last updated:** 2026-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06921837

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06921837, "A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06921837. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*